Search Results - "STRINA, Carla"

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study by Schettini, Francesco, Sobhani, Navid, Ianza, Anna, Triulzi, Tiziana, Molteni, Alfredo, Lazzari, Maria Chiara, Strina, Carla, Milani, Manuela, Corona, Silvia Paola, Sirico, Marianna, Bernocchi, Ottavia, Giudici, Fabiola, Cappelletti, Maria Rosaria, Ciruelos, Eva, Jerusalem, Guy, Loi, Sherine, Fox, Stephen B., Generali, Daniele

“…Purpose mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of…”
Get full text

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib by Schettini, Francesco, De Bonis, Maria Valeria, Strina, Carla, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Ciliberto, Ignazio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ungari, Marco, Locci, Mariavittoria, Paris, Ida, Scambia, Giovanni, Ruocco, Gianpaolo, Generali, Daniele

“…Mathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth…”
Get full text

Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study by Schettini, Francesco, Saracchini, Silvana, Bassini, Anna, Marus, Wally, Corsetti, Serena, Specogna, Ilaria, Bertola, Manuela, Micheli, Elvia, Wirtz, Ralph M., Laible, Mark, Şahin, Uğur, Strina, Carla, Milani, Manuela, Aguggini, Sergio, Tancredi, Richard, Fiorio, Elena, Sulfaro, Sandro, Generali, Daniele

“…Neoadjuvant chemotherapy (NACT) is widely used in the treatment of triple-negative and HER2-positive breast cancer (BC), but its use in estrogen receptor (ER)…”
Get full text

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study by D'Angelo, Alberto, Giudici, Fabiola, Chapman, Robert, Darlow, Jacob, Kilili, Huseyin, Sobhani, Navid, Cinelli, Mattia, Cappelletti, Maria Rosa, Strina, Carla, Milani, Manuela, Generali, Daniele

“…Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6 i), abemaciclib, palbociclib, and ribociclib, have been FDA-approved for the treatment of hormone…”
Get full text

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial by Schettini, Francesco, Corona, Silvia Paola, Giudici, Fabiola, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Ziglioli, Nicoletta, Aguggini, Sergio, Azzini, Carlo, Barbieri, Giuseppina, Cervoni, Valeria, Cappelletti, Maria Rosa, Molteni, Alfredo, Lazzari, Maria Chiara, Ferrero, Giuseppina, Ungari, Marco, Marasco, Elena, Bruson, Alice, Xumerle, Luciano, Zago, Elisa, Cerra, Davide, Loddo, Marco, Williams, Gareth H, Paris, Ida, Scambia, Giovanni, Generali, Daniele

“…Olaparib is effective in metastatic triple negative breast cancer (TNBC) carrying germline mutations in DNA damage repair (DDR) genes (g -mut). The OLTRE…”
Get full text

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature by Bernocchi, Ottavia, Sirico, Marianna, Corona, Silvia Paola, Strina, Carla, Milani, Manuela, Cappelletti, Maria Rosa, Ferrero, Giuseppina, Ziglioli, Nicoletta, Cervoni, Valeria, Macchiavelli, Andrea, Roviello, Giandomenico, Generali, Daniele

“…Precision medicine is based on molecular and genotypic patient characterization to define specific target treatment. BRAF mutation is an oncogenic driver, and…”
Get full text

Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients by Generali, Daniele, Rocca, Andrea, Strina, Carla, Milani, Manuela, Fiorino, Enrico, Cervoni, Valeria, Azzini, Carlo, Saracino, Antonella, Ciliberto, Ingnazio, Ziglioli, Nicoletta, Alberio, Marzia, Giudici, Fabiola, Dester, Martina, Ciani, Oriana, Fornaro, Giulia, Aguggini, Sergio, Dreezen, Christa, Pronin, Darina, Ende, Stefanie

“…The aim of this study was to assess the prognostic performance of the 70-gene signature, MammaPrint, in an Italian single-center prospective cohort of…”
Get full text

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer by Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paola, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni

Get full text

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer by Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paola, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni

“…The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer…”
Get full text

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer by Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paolo, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni

Get full text

COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry by Garrigós, Laia, Saura, Cristina, Martinez-Vila, Clara, Zambelli, Alberto, Bower, Mark, Pistilli, Barbara, Lambertini, Matteo, Ottaviani, Diego, Diamantis, Nikolaos, Lumsden, Ailsa, Pernas, Sonia, Generali, Daniele, Seguí, Elia, Viñas, Gemma, Felip, Eudald, Sanchez, Ana, Rizzo, Gianpiero, Santoro, Armando, Cortellini, Alessio, Perone, Ylenia, Chester, John, Iglesias, Maria, Betti, Marta, Vincenzi, Bruno, Libertini, Michela, Mazzoni, Francesca, Zoratto, Federica, Berardi, Rossana, Guida, Annalisa, Wuerstlein, Rachel, Loizidou, Angela, Sharkey, Rachel, Aguilar Company, Juan, Matas, Marta, Saggia, Chiara, Chiudinelli, Lorenzo, Colomba-Blameble, Emeline, Galazi, Myria, Mukherjee, Uma, Van Hemelrijck, Mieke, Marin, Mar, Strina, Carla, Prat, Aleix, Pla, Helena, Ciruelos, Eva Maria, Bertuzzi, Alexia, del Mastro, Lucia, Porzio, Giampiero, Newsom-Davis, Thomas, Ruiz, Isabel, Delany, Maria Belen, Krengli, Marco, Fotia, Vittoria, Viansone, Alessandro, Chopra, Neha, Romeo, Margarita, Salazar, Ramon, Perez, Ignacio, d’Avanzo, Francesca, Franchi, Michela, Milani, Manuela, Pommeret, Fanny, Tucci, Marco, Pedrazzoli, Paolo, Harbeck, Nadia, Ferrante, Daniela, Pinato, David J., Gennari, Alessandra

“…Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have…”
Get full text

Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study by Schettini, Francesco, Fontana, Alessandra, Gattazzo, Federica, Strina, Carla, Milani, Manuela, Cappelletti, Maria Rosa, Cervoni, Valeria, Morelli, Lorenzo, Curigliano, Giuseppe, Iebba, Valerio, Generali, Daniele

“…Cyclin-dependent kinase (CDK)4/6-inhibitors with endocrine therapy represent the standard of treatment of hormone receptor-positive(HR+)/human epidermal growth…”
Get full text

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study by Schettini, Francesco, Sirico, Marianna, Loddo, Marco, Williams, Gareth H, Hardisty, Keeda-Marie, Scorer, Paul, Thatcher, Robert, Rivera, Pablo, Milani, Manuela, Strina, Carla, Ferrero, Giuseppina, Ungari, Marco, Bottin, Cristina, Zanconati, Fabrizio, de Manzini, Nicolò, Aguggini, Sergio, Tancredi, Richard, Fiorio, Elena, Fioravanti, Antonio, Scaltriti, Maurizio, Generali, Daniele

“…The identification of the most appropriate targeted therapies for advanced cancers is challenging. We performed a molecular profiling of metastatic solid…”
Get full text

Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study by Corona, Silvia P, Giudici, Fabiola, Jerusalem, Guy, Ciruelos, Eva, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Dester, Martina, Ziglioli, Nicoletta, Barbieri, Giuseppina, Cervoni, Valeria, Montemurro, Filippo, Generali, Daniele

Get full text

Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR by Generali, Daniele, Corona, Silvia Paola, Pusztai, Lajos, Rouzier, Roman, Allevi, Giovanni, Aguggini, Sergio, Milani, Manuela, Strina, Carla, Frati, Albane

“…Introduction Neoadjuvant hormonal therapy is generally considered a valid option for hormone receptor positive breast cancer (BC) patients who are unfit for…”
Get full text

Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study by Corona, Silvia P., Giudici, Fabiola, Jerusalem, Guy, Ciruelos, Eva, Strina, Carla, Sirico, Marianna, Bernocchi, Ottavia, Milani, Manuela, Dester, Martina, Ziglioli, Nicoletta, Barbieri, Giuseppina, Cervoni, Valeria, Montemurro, Filippo, Generali, Daniele

“…INTRODUCTIONReliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the…”
Get full text

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer by Feldinger, Katharina, Generali, Daniele, Kramer-Marek, Gabriela, Gijsen, Merel, Ng, T B, Wong, Jack Ho, Strina, Carla, Cappelletti, Mariarosa, Andreis, Daniele, Li, Ji-Liang, Bridges, Esther, Turley, Helen, Leek, Russell, Roxanis, Ioannis, Capala, Jacek, Murphy, Gillian, Harris, Adrian L, Kong, Anthony

“…Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a…”
Get full text

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer by Azad, Abul, Arshad, Maryam, Generali, Daniele, Feldinger, Katharina, Gijsen, Merel, Strina, Carla, Cappelletti, Mariarosa, Andreis, Daniele, Leek, Russell, Haider, Syed, Kellokumpu‐Lehtinen, Pirkko‐Liisa, Roxanis, Ioannis, Harris, Adrian Llewellyn, Shaaban, Abeer Mahmoud, Joensuu, Heikki, Kong, Anthony

Get full text

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer by Mohd Nafi, Siti Norasikin, Generali, Daniele, Kramer-Marek, Gabriela, Gijsen, Merel, Strina, Carla, Cappelletti, Mariarosa, Andreis, Daniele, Haider, Syed, Li, Ji-Liang, Bridges, Esther, Capala, Jacek, Ioannis, Roxanis, Harris, Adrian L, Kong, Anthony

“…The role of HER4 in breast cancer is controversial and its role in relation to trastuzumab resistance remains unclear. We showed that trastuzumab treatment and…”
Get full text

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? by Corona, Silvia Paola, Roviello, Giandomenico, Strina, Carla, Milani, Manuela, Allevi, Giovanni, Aguggini, Sergio, Zanoni, Daniele, Generali, Daniele

“…Treatment of triple-negative breast cancer (TNBC) imposes great challenges, due to a lack of molecular targets. While use of gonadotropin-releasing hormone…”
Get full text